Compare · BDSX vs CI
BDSX vs CI
Side-by-side comparison of Biodesix Inc. (BDSX) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 249.2x BDSX ($296.2M).
- CI has been more active in the news (7 items in the past 4 weeks vs 6 for BDSX).
- CI has more recent analyst coverage (25 ratings vs 9 for BDSX).
- Company
- Biodesix Inc.
- The Cigna Group
- Price
- $27.81+9.90%
- $279.37-0.35%
- Market cap
- $296.2M
- $73.81B
- 1M return
- +22.46%
- -
- 1Y return
- +198.90%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 7
- Recent ratings
- 9
- 25
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest BDSX
- Emeritus Director Schuler Jack W bought $366,992 worth of shares (15,000 units at $24.47) (SEC Form 4)
- Emeritus Director Schuler Jack W bought $665,940 worth of shares (27,600 units at $24.13) (SEC Form 4)
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces Second Quarter 2026 Results and Highlights
- Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
- Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
- Chairman Patience John converted options into 1,361 shares, increasing direct ownership by 6% to 25,383 units (SEC Form 4)
- Roth Capital initiated coverage on Biodesix with a new price target
- H.C. Wainwright initiated coverage on Biodesix with a new price target
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook